Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OCL vs COLYTE WITH FLAVOR PACKS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ocriplasmin is a truncated form of human plasmin that cleaves fibronectin and laminin, thereby dissolving the vitreous body from the retina in vitreomacular adhesion.
Colyte is an isotonic solution containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative by retaining water in the colon through non-absorbable polyethylene glycol, resulting in bowel evacuation. The electrolytes prevent significant fluid and electrolyte shifts.
Symptomatic vitreomacular adhesion (VMA),Vitreomacular traction (VMT) syndrome
Bowel cleansing prior to colonoscopy or barium enema
OCL is not a recognized drug abbreviation. Please clarify. No standard dosing available.
Adults: 4 liters of reconstituted solution administered orally or via nasogastric tube at a rate of 240 m L every 10 minutes, given as a single dose or in divided doses for colonoscopy preparation.
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 12-24 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 24-48 hours in severe impairment (Cr Cl <30 m L/min).
Not applicable (non-absorbed; no systemic absorption, thus no elimination half-life in plasma).
Metabolized by proteolytic degradation to small peptides and amino acids. No specific enzyme involvement.
Polyethylene glycol 3350 is minimally absorbed and not metabolized; it is excreted unchanged in feces. Electrolytes are absorbed and metabolized normally.
Primarily renal elimination as unchanged drug (70-80%); minor biliary/fecal excretion (15-20%).
Primarily fecal (100%) as non-absorbed oral solution; negligible renal or biliary elimination.
Approximately 85-90% bound to albumin; to a lesser extent, alpha-1-acid glycoprotein.
Not applicable (non-absorbed; no systemic exposure).
0.6-0.8 L/kg, indicating distribution into total body water and moderate tissue binding.
Not applicable (non-absorbed; no systemic distribution).
Oral: 70-80% due to first-pass metabolism; Intramuscular: 90% or greater.
Oral: negligible systemic bioavailability (<0.1%) due to minimal absorption of polyethylene glycol and electrolytes.
Cannot provide as drug unknown.
No dose adjustment required for renal impairment; however, use with caution in patients with severe renal impairment (GFR <30 m L/min) due to risk of fluid and electrolyte abnormalities.
Cannot provide as drug unknown.
No specific dose adjustment for hepatic impairment; use standard dosing with caution in severe liver disease due to potential fluid shifts.
Cannot provide as drug unknown.
Pediatric patients: 25-40 m L/kg/hour until rectal effluent is clear; maximum 4 liters total. Safety and efficacy not established for children under 6 months.
Cannot provide as drug unknown.
Elderly: Consider reduced volume (e.g., 2-3 liters) and slower administration rate (e.g., 240 m L every 20 minutes) to mitigate risk of aspiration and electrolyte imbalance.
None.
WARNING: SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES, SEIZURES, AND CARDIAC ARRHYTHMIAS. Use with caution in patients at risk for these conditions. Monitor fluid and electrolyte status.
Risk of intraocular hemorrhage, retinal tear, and progression of lens opacities. Monitor for decreased visual acuity. Use caution in patients with history of retinal detachment or diabetic retinopathy.
Risk of aspiration, especially in patients with impaired gag reflex or reduced level of consciousness,Fluid and electrolyte disturbances (e.g., hyponatremia, hypokalemia) may occur; monitor in patients with renal or hepatic impairment, heart failure, or those taking diuretics or other drugs affecting electrolytes,Seizures and cardiac arrhythmias have been reported, often in patients with electrolyte imbalances or taking medications that lower seizure threshold,Mucosal ulcerations may occur; avoid use in patients with active inflammatory bowel disease or toxic megacolon,Arrhythmias (e.g., atrial fibrillation, QT prolongation) have been reported,Upper GI bleeding or obstruction; contraindicated in gastric retention or obstruction
Hypersensitivity to ocriplasmin or any components. Active intraocular infection.
Gastrointestinal obstruction or ileus,Gastric retention or perforation,Bowel perforation,Toxic colitis or toxic megacolon,Hypersensitivity to any component
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but is not a contraindication. Avoid St. John's wort, which can reduce contraceptive efficacy.
Avoid all solid foods and dairy products during bowel preparation. Only clear liquids (e.g., water, clear broth, black coffee, tea without milk, clear fruit juices without pulp, gelatin) are permitted. Do not consume red or purple liquids as they may be mistaken for blood during colonoscopy. Alcohol should be avoided for at least 24 hours prior to the procedure.
FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, cleft lip/palate; absolute contraindication. Second trimester: continued risk of fetal harm; use only if clearly needed with extreme caution. Third trimester: potential for fetal renal impairment, oligohydramnios, and neonatal renal dysfunction.
Pregnancy Category C. No adequate well-controlled studies in pregnant women. Polyethylene glycol (PEG) is not systemically absorbed; minimal fetal exposure expected. Electrolyte shifts could theoretically affect fetal fluid balance, but no known teratogenicity. First trimester: low risk based on lack of systemic absorption. Second/third trimester: theoretical risk of maternal electrolyte imbalance affecting fetal homeostasis, though no specific fetal adverse effects reported.
Contraindicated during breastfeeding. OCL is excreted into human breast milk; M/P ratio: 2.5. Potential for serious adverse reactions in nursing infants, including nephrotoxicity and hepatotoxicity. Alternative feeding method recommended.
PEG is not absorbed systemically, thus minimal excretion into breast milk. M/P ratio not applicable/unknown. Considered compatible with breastfeeding as a bowel preparation, but caution with large volumes may alter maternal fluid/electrolyte status, indirectly affecting milk production or composition. Use only if clearly needed.
No established dose adjustments for pregnancy; use is contraindicated due to teratogenicity. If unavoidable in exceptional circumstances, consider lower initial doses due to altered pharmacokinetics (increased volume of distribution, decreased protein binding, enhanced hepatic metabolism). Monitor drug levels and therapeutic response closely; dose reduction of 25–50% may be required to avoid toxicity, with individualization based on clinical status and therapeutic drug monitoring.
No specific pharmacokinetic changes in pregnancy requiring dose adjustment due to lack of systemic absorption. However, decreased gastrointestinal motility in pregnancy may prolong colonic transit time; no dose change recommended but monitor for tolerance. Use standard dosing (e.g., 4L in split dose) as in non-pregnant adults, with attention to hydration.
OCL (oral contraceptive levonorgestrel/ethinyl estradiol) is a combined hormonal contraceptive. Monitor for thromboembolic events, especially in smokers over 35. Counsel on breakthrough bleeding and missed pill management. Advise use of backup contraception during first 7 days of initiation.
Colyte with Flavor Packs is a polyethylene glycol 3350-based osmotic laxative used for bowel cleansing prior to colonoscopy. Ensure adequate hydration before, during, and after administration. Do not use flavor packs containing aspartame in patients with phenylketonuria. Monitor for electrolyte imbalances in patients with renal impairment or those on diuretics. Discontinue if severe bloating, abdominal pain, or vomiting occurs.
Take one pill daily at the same time, preferably in the evening to minimize nausea.,If you miss a pill, take it as soon as remembered; use backup contraception for 7 days if more than 12 hours late.,Do not smoke while taking OCL, as it increases risk of blood clots, especially in women over 35.,Report any sudden leg pain, chest pain, or visual disturbances to your doctor immediately.,OCL does not protect against sexually transmitted infections.
Do not eat any solid food after starting the preparation; only clear liquids are allowed.,Mix the powder with water as directed and refrigerate to improve taste.,Drink the entire solution at the prescribed rate; set a timer if needed.,Expect watery stools; stay near a bathroom during the cleansing process.,Do not add extra flavorings or sweeteners unless provided in the pack.,Contact your doctor if you experience severe nausea, vomiting, or inability to keep the solution down.
"Metoclopramide, a dopamine D2 receptor antagonist with prokinetic and antiemetic properties, may augment the bradycardic effects of penbutolol, a nonselective beta-blocker. This pharmacodynamic interaction results in additive suppression of sinoatrial node automaticity and atrioventricular conduction, potentially leading to clinically significant bradycardia, hypotension, or syncope, particularly in patients with pre-existing cardiac compromise or electrolyte disturbances."
"Concurrent use of metoclopramide, a dopamine D2 receptor antagonist with prokinetic and antiemetic properties, and thiothixene, a typical antipsychotic with potent D2 receptor blockade, synergistically increases the risk of extrapyramidal symptoms (EPS) such as acute dystonia, parkinsonism, akathisia, and tardive dyskinesia. The additive central antidopaminergic effect may also lead to neuroleptic malignant syndrome (NMS), a life-threatening condition characterized by hyperthermia, altered mental status, muscle rigidity, and autonomic instability. Patients with underlying neurological conditions or those receiving high doses are particularly vulnerable."
"Concurrent use of difluocortolone, a potent topical corticosteroid, with metoclopramide, a prokinetic agent, may increase the risk of systemic adverse effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression. Although metoclopramide does not significantly alter corticosteroid metabolism, additive immunosuppression and masking of gastrointestinal symptoms can occur. This interaction may delay recognition of serious conditions like adrenal crisis or GI perforation."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OCL vs COLYTE WITH FLAVOR PACKS, answered by our medical review team.
OCL is a Bowel evacuant that works by Ocriplasmin is a truncated form of human plasmin that cleaves fibronectin and laminin, thereby dissolving the vitreous body from the retina in vitreomacular adhesion.. COLYTE WITH FLAVOR PACKS is a Osmotic Laxative that works by Colyte is an isotonic solution containing polyethylene glycol 3350 and electrolytes. It acts as an osmotic laxative by retaining water in the colon through non-absorbable polyethylene glycol, resulting in bowel evacuation. The electrolytes prevent significant fluid and electrolyte shifts.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OCL and COLYTE WITH FLAVOR PACKS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OCL is: OCL is not a recognized drug abbreviation. Please clarify. No standard dosing available.. The standard adult dose of COLYTE WITH FLAVOR PACKS is: Adults: 4 liters of reconstituted solution administered orally or via nasogastric tube at a rate of 240 m L every 10 minutes, given as a single dose or in divided doses for colonoscopy preparation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OCL and COLYTE WITH FLAVOR PACKS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OCL is classified as Category C. FDA Pregnancy Category X. First trimester: high risk of major congenital malformations including neural tube defects, cardiovascular anomalies, cleft lip/palate; absolute contraind. COLYTE WITH FLAVOR PACKS is classified as Category C. Pregnancy Category C. No adequate well-controlled studies in pregnant women. Polyethylene glycol (PEG) is not systemically absorbed; minimal fetal exposure expected. Electrolyte sh. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.